J. Schneider

发表

Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.

W. Ageno, L. Mantovani, A. Turpie, 2016, The Lancet. Haematology.

XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis

W. Ageno, L. Mantovani, A. Turpie, 2014, Thrombosis Journal.

Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA‐LEA noninterventional studies

W. Ageno, L. Mantovani, A. Turpie, 2021, Research and practice in thrombosis and haemostasis.

Safety and effectiveness of rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep vein thrombosis in routine clinical practice Subgroup analysis of XALIA-DE for Germany

R. Kreutz, R. Kreutz, J. Beyer-Westendorf, 2017 .

Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study.

W. Ageno, L. Mantovani, A. Turpie, 2017, Thrombosis research.

Treatment of venous thromboembolism with rivaroxaban in relation to body weight

M. Prins, P. Prandoni, M. Di Nisio, 2016, Thrombosis and Haemostasis.

Patient-Reported Treatment Experience with Oral Rivaroxaban: Results from the Noninterventional XALIA Study of Deep-Vein Thrombosis

W. Ageno, L. Mantovani, A. Turpie, 2018, TH Open.

fixed-dose rivaroxaban is not associated with increased recurrent venous thromboembolism or major bleeding in patients with a high or low body weight : As099

M. Prins, A. Riera-Mestre, A. Lensing, 2015 .

Patient Management Strategies and Long-Term Outcomes in Isolated Distal Deep-Vein Thrombosis versus Proximal Deep-Vein Thrombosis: Findings from XALIA

W. Ageno, L. Mantovani, A. Turpie, 2019, TH Open.

XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America.

W. Ageno, L. Mantovani, A. Turpie, 2019, Thrombosis research.

Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis.

W. Ageno, L. Mantovani, A. Turpie, 2019, European journal of internal medicine.

Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry

Morten Wang Fagerland, D. Atar, A. Camm, 2017, European heart journal. Cardiovascular pharmacotherapy.

Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE

W. Ageno, L. Mantovani, A. Turpie, 2017, TH Open.

Safety and effectiveness of rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep vein thrombosis in routine clinical practice Sicherheit und Wirksamkeit von Rivaroxaban im Vergleich zur Standard-Antikoagulation bei tiefen Venenthrombosen im klinischen Alltag

J. Beyer-Westendorf, S. Haas, R. Kreutz, 2016, Phlebologie.

Treatment of venous thromboembolism with rivaroxaban in relation to body weight

M. Prins, P. Prandoni, P. Wells, 2016, Thrombosis and Haemostasis.

XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis

W. Ageno, L. Mantovani, A. Turpie, 2014, Thrombosis Journal.

Real life studies and good clinical practice - Authors' reply.

W. Ageno, L. Mantovani, A. Turpie, 2016, The Lancet. Haematology.